Macrophages in solid organ transplantation

Vascular Cell

Volumn 6, Issue 1, 2014, Pages

  Jiang, Xinguo ^a,b   Tian, Wen ^a   Sung, Yon K ^a   Qian, Jin ^a   Nicolls, Mark R ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Acute rejection; Graft vascular disease; Ischemia reperfusion injury; Macrophage; Transplantation

Indexed keywords

ACUTE GRAFT REJECTION; GRAFT FAILURE; GRAFT VASCULAR DISEASE; HUMAN; INFLAMMATION; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SOLID ORGAN TRANSPLANTATION; TISSUE REPAIR; VASCULAR DISEASE;

EID: 84898443769     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-6-5     Document Type: Review

References (120)

1. Metchnikoff É Immunity in Infective Diseases London: Cambridge University Press 1905
2. Macrophage biology in development, homeostasis and disease. Wynn TA, Chawla A, Pollard JW, Nature 2013 496 7446 445 455 10.1038/nature12034 23619691
3. Interleukin-4- and interleukin-13-mediated alternatively activated macrophages: roles in homeostasis and disease. Van Dyken SJ, Locksley RM, Annu Rev Immunol 2013 31 317 343 10.1146/annurev-immunol-032712-095906 23298208
4. Transcriptional regulation of macrophage polarization: enabling diversity with identity. Lawrence T, Natoli G, Nat Rev Immunol 2011 11 11 750 761 10.1038/nri3088 22025054
5. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE, Science 2011 332 6035 1284 1288 10.1126/science.1204351 21566158
6. Protective and pathogenic functions of macrophage subsets. Murray PJ, Wynn TA, Nat Rev Immunol 2011 11 11 723 737 10.1038/nri3073 21997792
7. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. Stein M, Keshav S, Harris N, Gordon S, J Exp Med 1992 176 1 287 292 10.1084/jem.176.1.287 1613462
8. Alternative activation of macrophages. Gordon S, Nat Rev Immunol 2003 3 1 23 35 10.1038/nri978 12511873 (Pubitemid 37328697)
9. Alternative activation of macrophages: mechanism and functions. Gordon S, Martinez FO, Immunity 2010 32 5 593 604 10.1016/j.immuni.2010.05.007 20510870
10. Exploring the full spectrum of macrophage activation. Mosser DM, Edwards JP, Nat Rev Immunol 2008 8 12 958 969 10.1038/nri2448 19029990
11. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Broichhausen C, Riquelme P, Geissler EK, Hutchinson JA, Curr Opin Organ Transplant 2012 17 4 332 342 22790067
12. Transcriptome-based network analysis reveals a spectrum model of human macrophage activation. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, De Nardo D, Gohel TD, Emde M, Schmidleithner L, Ganesan H, Nino-Castro A, Mallmann MR, Labzin L, Theis H, Kraut M, Beyer M, Latz E, Freeman TC, Ulas T, Schultze JL, Immunity 2014 40 2 274 288 10.1016/j.immuni.2014.01.006 24530056
13. Identity and cytotoxic capacity of cells infiltrating renal allografts. Strom TB, Tilney NL, Carpenter CB, Busch GJ, N Engl J Med 1975 292 24 1257 1263 10.1056/NEJM197506122922402 1093024
14. Composition and in vitro cytotoxicity of cellular infiltrates in rejecting human kidney allografts. von Willebrand E, Hayry P, Cell Immunol 1978 41 2 358 372 10.1016/0008-8749(78)90233-2 215332 (Pubitemid 9128046)
15. Graft vascular disease: immune response meets the vessel wall. Mitchell RN, Annu Rev Pathol 2009 4 19 47 10.1146/annurev.pathol.3.121806.151449 18717641
16. Monocytes/macrophages in renal allograft rejection. Magil AB, Transplant Rev (Orlando) 2009 23 4 199 208 10.1016/j.trre.2009.06.005 19640696
17. The role of macrophages in allograft rejection. Wyburn KR, Jose MD, Wu H, Atkins RC, Chadban SJ, Transplantation 2005 80 12 1641 1647 10.1097/01.tp.0000173903.26886.20 16378052 (Pubitemid 43053983)
18. Macrophages: contributors to allograft dysfunction, repair, or innocent bystanders? Mannon RB, Curr Opin Organ Transplant 2012 17 1 20 25 10.1097/MOT.0b013e32834ee5b6 22157320
19. Adenovirus-mediated HIF-1alpha gene transfer promotes repair of mouse airway allograft microvasculature and attenuates chronic rejection. Jiang X, Khan MA, Tian W, Beilke J, Natarajan R, Kosek J, Yoder MC, Semenza GL, Nicolls MR, J Clin Invest 2011 121 6 2336 2349 10.1172/JCI46192 21606594
20. The role of autoimmunity in obliterative bronchiolitis after lung transplantation. Weber DJ, Wilkes DS, Am J Physiol Lung Cell Mol Physiol 2013 304 5 307 L311 10.1152/ajplung.00378.2012 23262227
21. Kidney transplantation and the ageing immune system. McKay D, Jameson J, Nat Rev Nephrol 2012 8 12 700 708 23147756
22. Ischemia and reperfusion-from mechanism to translation. Eltzschig HK, Eckle T, Nat Med 2011 17 11 1391 1401 10.1038/nm.2507 22064429
23. Hypoxia and inflammation. Eltzschig HK, Carmeliet P, N Engl J Med 2011 364 7 656 665 10.1056/NEJMra0910283 21323543
24. Cell death. Hotchkiss RS, Strasser A, McDunn JE, Swanson PE, N Engl J Med 2009 361 16 1570 1583 10.1056/NEJMra0901217 19828534
25. Sterile inflammation: sensing and reacting to damage. Chen GY, Nunez G, Nat Rev Immunol 2010 10 12 826 837 10.1038/nri2873 21088683
26. Modifying graft immunogenicity and immune response prior to transplantation: potential clinical applications of donor and graft treatment. Martins PN, Chandraker A, Tullius SG, Trans Int Official J Eur Soc Org Trans 2006 19 5 351 359
27. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK, Nephrol Dial Transplant 2006 21 5 1231 1239 10.1093/ndt/gfk047 16410269
28. Keap1-Nrf2 Complex in Ischemia-Induced Hepatocellular Damage of Mouse Liver Transplants. Ke B, Shen XD, Zhang Y, Ji H, Gao F, Yue S, Kamo N, Zhai Y, Yamamoto M, Busuttil RW, Kupiec-Weglinski JW, J Hepatol 2013 59 6 1200 7 10.1016/j.jhep.2013.07.016 23867319
29. Inhibition of sphingosine kinase-2 suppresses inflammation and attenuates graft injury after liver transplantation in rats. Liu Q, Rehman H, Shi Y, Krishnasamy Y, Lemasters JJ, Smith CD, Zhong Z, PLoS One 2012 7 7 41834 10.1371/journal.pone.0041834 22848628
30. Combined donor simvastatin and methylprednisolone treatment prevents ischemia-reperfusion injury in rat cardiac allografts through vasculoprotection and immunomodulation. Tuuminen R, Syrjala S, Krebs R, Arnaudova R, Rouvinen E, Nykanen AI, Lemstrom KB, Transplantation 2013 95 9 1084 1091 10.1097/TP.0b013e3182881b61 23466635
31. Alveolar macrophage activation is a key initiation signal for acute lung ischemia-reperfusion injury. Zhao M, Fernandez LG, Doctor A, Sharma AK, Zarbock A, Tribble CG, Kron IL, Laubach VE, Am J Physiol Lung Cell Mol Physiol 2006 291 5 1018 1026 10.1152/ajplung.00086.2006 16861385 (Pubitemid 44772064)
32. Attenuation of Lung Ischemia-Reperfusion Injury by Rho-Associated Kinase Inhibition in a Rat Model of Lung Transplantation. Kohno M, Watanabe M, Goto T, Kamiyama I, Ohtsuka T, Tasaka S, Sawafuji M, Ann Thorac Cardiovasc Surg 2013 In Press
33. Effector mechanisms of rejection. Moreau A, Varey E, Anegon I, Cuturi MC, Cold Spring Harb Perspect Med. 2013 3 015461 10.1101/cshperspect.a015461 24186491
34. The role of toll-like receptors in macrophages. McCoy CE, O'Neill LA, Front Biosci 2008 13 62 70 10.2741/2660 17981528 (Pubitemid 351594763)
35. Toll-like receptor 4-dependent microglial activation mediates spinal cord ischemia-reperfusion injury. Bell MT, Puskas F, Agoston VA, Cleveland JC Jr, Freeman KA, Gamboni F, Herson PS, Meng X, Smith PD, Weyant MJ, Fullerton DA, Reece TB, Circulation 2013 128 26 Suppl 1 152 S156 24030400
36. Hmgb1-TLR4-IL-23-IL-17A axis promote ischemia-reperfusion injury in a cardiac transplantation model. Zhu H, Li J, Wang S, Liu K, Wang L, Huang L, Transplantation 2013 95 12 1448 1454 10.1097/TP.0b013e318293b7e1 23677049
37. Peroxiredoxin family proteins are key initiators of post-ischemic inflammation in the brain. Shichita T, Hasegawa E, Kimura A, Morita R, Sakaguchi R, Takada I, Sekiya T, Ooboshi H, Kitazono T, Yanagawa T, Ishii T, Takahashi H, Mori S, Nishibori M, Kuroda K, Akira S, Miyake K, Yoshimura A, Nat Med 2012 18 6 911 917 10.1038/nm.2749 22610280
38. Macrophage Wnt7b is critical for kidney repair and regeneration. Lin SL, Li B, Rao S, Yeo EJ, Hudson TE, Nowlin BT, Pei H, Chen L, Zheng JJ, Carroll TJ, Pollard JW, McMahon AP, Lang RA, Duffield JS, Proc Natl Acad Sci USA 2010 107 9 4194 4199 10.1073/pnas.0912228107 20160075
39. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. Menke J, Iwata Y, Rabacal WA, Basu R, Yeung YG, Humphreys BD, Wada T, Schwarting A, Stanley ER, Kelley VR, J Clin Invest 2009 119 8 2330 2342 10.1172/JCI39087 19587445
40. Prednisolone as preservation additive prevents from ischemia reperfusion injury in a rat model of orthotopic lung transplantation. Paulus P, Holfeld J, Urbschat A, Mutlak H, Ockelmann PA, Tacke S, Zacharowski K, Reissig C, Stay D, Scheller B, PLoS One 2013 8 8 73298 10.1371/journal.pone.0073298 24009745
41. Macrophages are involved in the protective role of human umbilical cord-derived stromal cells in renal ischemia-reperfusion injury. Li W, Zhang Q, Wang M, Wu H, Mao F, Zhang B, Ji R, Gao S, Sun Z, Zhu W, Qian H, Chen Y, Xu W, Stem Cell Res 2013 10 3 405 416 10.1016/j.scr.2013.01.005 23466564
42. Distinct macrophage phenotypes contribute to kidney injury and repair. Lee S, Huen S, Nishio H, Nishio S, Lee HK, Choi BS, Ruhrberg C, Cantley LG, J Am Soc Nephrol 2011 22 2 317 326 10.1681/ASN.2009060615 21289217
43. Leukotriene B4 type-1 receptor signaling promotes liver repair after hepatic ischemia/reperfusion injury through the enhancement of macrophage recruitment. Ohkubo H, Ito Y, Minamino T, Mishima T, Hirata M, Hosono K, Shibuya M, Yokomizo T, Shimizu T, Watanabe M, Majima M, FASEB J 2013 27 8 3132 3143 10.1096/fj.13-227421 23629862
44. The mechanisms of acute transplant rejection revisited. Ponticelli C, J Nephrol 2012 25 2 150 158 10.5301/jn.5000048 22101676
45. Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis. Drachenberg CB, Papadimitriou JC, Transplantation 2013 95 9 1073 1083 10.1097/TP.0b013e31827e6b45 23370711
46. Monocyte infiltration and kidney allograft dysfunction during acute rejection. Girlanda R, Kleiner DE, Duan Z, Ford EA, Wright EC, Mannon RB, Kirk AD, Am J Trans Official J Am Soc Trans Am Soc Trans Surg 2008 8 3 600 607 10.1111/j.1600-6143.2007.02109.x (Pubitemid 351287541)
47. Macrophages act as effectors of tissue damage in acute renal allograft rejection. Jose MD, Ikezumi Y, van Rooijen N, Atkins RC, Chadban SJ, Transplantation 2003 76 7 1015 1022 10.1097/01.TP.0000083507.67995.13 14557746 (Pubitemid 37280827)
48. Targeted inhibition of renal Rho kinase reduces macrophage infiltration and lymphangiogenesis in acute renal allograft rejection. Poosti F, Yazdani S, Dolman ME, Kok RJ, Chen C, Ding G, Lacombe M, Prakash J, van den Born J, Hillebrands JL, van Goor H, de Borst MH, Eur J Pharmacol 2012 694 1-3 111 119 22964464
49. Morphologic and immunohistochemical findings in antibody-mediated rejection of the cardiac allograft. Fishbein GA, Fishbein MC, Human Immunol 2012 73 12 1213 1217 10.1016/j.humimm.2012.07.011
50. Intravascular macrophages in cardiac allograft biopsies for diagnosis of early and late antibody-mediated rejection. Fedrigo M, Feltrin G, Poli F, Frigo AC, Benazzi E, Gambino A, Tona F, Caforio AL, Castellani C, Toscano G, Gerosa G, Thiene G, Angelini A, J Heart Lung Transplant Official Pub Int Soc Heart Transplantat 2013 32 4 404 409 10.1016/j.healun.2012.12.017
51. CD99 plays a major role in the migration of monocytes through endothelial junctions. Schenkel AR, Mamdouh Z, Chen X, Liebman RM, Muller WA, Nat Immunol 2002 3 2 143 150 10.1038/ni749 11812991 (Pubitemid 34141444)
52. Blockade of p-selectin is sufficient to reduce MHC I antibody-elicited monocyte recruitment in vitro and in vivo. Valenzuela NM, Hong L, Shen XD, Gao F, Young SH, Rozengurt E, Kupiec-Weglinski JW, Fishbein MC, Reed EF, Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg 2013 13 2 299 311 10.1111/ajt.12016
53. Monocyte chemotactic peptide-1 expression and monocyte infiltration in acute renal transplant rejection. Grandaliano G, Gesualdo L, Ranieri E, Monno R, Stallone G, Schena FP, Transplantation 1997 63 3 414 420 10.1097/00007890- 199702150-00015 9039933 (Pubitemid 27086035)
54. Macrophage migration inhibitory factor expression in human renal allograft rejection. Lan HY, Yang N, Brown FG, Isbel NM, Nikolic-Paterson DJ, Mu W, Metz CN, Bacher M, Atkins RC, Bucala R, Transplantation 1998 66 11 1465 1471 10.1097/00007890-199812150-00009 9869087 (Pubitemid 29014025)
55. Macrophage colony-stimulating factor expression and macrophage accumulation in renal allograft rejection. Le Meur Y, Jose MD, Mu W, Atkins RC, Chadban SJ, Transplantation 2002 73 8 1318 1324 10.1097/00007890-200204270-00022 11981428 (Pubitemid 34454282)
56. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Jose MD, Le Meur Y, Atkins RC, Chadban SJ, Am J Transplant 2003 3 3 294 300 10.1034/j.1600-6143. 2003.00068.x 12614284 (Pubitemid 36407047)
57. Impact of chemokine receptor CX3CR1 in human renal allograft rejection. Hoffmann U, Bergler T, Segerer S, Rummele P, Kruger B, Banas MC, Reinhold S, Banas B, Kramer BK, Transplant Immunol 2010 23 4 204 208 10.1016/j.trim.2010.06. 006
58. Blocking of CCR5 and CXCR3 suppresses the infiltration of macrophages in acute renal allograft rejection. Kakuta Y, Okumi M, Miyagawa S, Tsutahara K, Abe T, Yazawa K, Matsunami K, Otsuka H, Takahara S, Nonomura N, Transplantation 2012 93 1 24 31 10.1097/TP.0b013e31823aa585 22124337
59. CCR5 blockade modulates inflammation and alloimmunity in primates. Schroder C, Pierson RN 3rd, Nguyen BN, Kawka DW, Peterson LB, Wu G, Zhang T, Springer MS, Siciliano SJ, Iliff S, Ayala JM, Lu M, Mudgett JS, Lyons K, Mills SG, Miller GG, Singer II, Azimzadeh AM, DeMartino JA, J Immunol 2007 179 4 2289 2299 17675490
60. RANTES chemokine expression is related to acute cardiac cellular rejection and infiltration by CD45RO T-lymphocytes and macrophages. Azzawi M, Hasleton PS, Geraghty PJ, Yonan N, Krysiak P, El-Gammal A, Deiraniya AK, Hutchinson IV, J Heart Lung Transplant Official Pub Int Soc Heart Transplant 1998 17 9 881 887 (Pubitemid 28440850)
61. An analysis of monocyte/macrophage subsets and granulocyte-macrophage colony-stimulating factor expression in renal allograft biopsies. Kajiwara I, Kawamura K, Takebayashi S, Nephron 1996 73 4 536 543 8856248 (Pubitemid 26258185)
62. Modulation of in vivo alloreactivity by inhibition of inducible nitric oxide synthase. Worrall NK, Lazenby WD, Misko TP, Lin TS, Rodi CP, Manning PT, Tilton RG, Williamson JR, Ferguson TB Jr, J Exp Med 1995 181 1 63 70 10.1084/jem.181.1.63 7528779
63. Evidence for increased nitric oxide production after liver transplantation in humans. Ioannidis I, Hellinger A, Dehmlow C, Rauen U, Erhard J, Eigler FW, De Groot H, Transplantation 1995 59 9 1293 1297 10.1097/00007890-199505000-00012 7762064
64. NOX 100, a nitric oxide scavenger, enhances cardiac allograft survival and promotes long-term graft acceptance. Roza AM, Cooper M, Pieper G, Hilton G, Dembny K, Lai CS, Lindholm P, Komorowski R, Felix C, Johnson C, Adams M, Transplantation 2000 69 2 227 231 10.1097/00007890-200001270-00006 10670631 (Pubitemid 30075279)
65. Nitric oxide as a regulatory and effector molecule in the immune system. Holan V, Krulova M, Zajicova A, Pindjakova J, Mol Immunol 2002 38 12-13 989 995 12009578 (Pubitemid 34496959)
66. Inhibition of macrophage activation and suppression of graft rejection by DTCM-glutarimide, a novel piperidine derived from the antibiotic 9-methylstreptimidone. Takeiri M, Tachibana M, Kaneda A, Ito A, Ishikawa Y, Nishiyama S, Goto R, Yamashita K, Shibasaki S, Hirokata G, Ozaki M, Todo S, Umezawa K, Inflamm Res 2011 60 9 879 888 10.1007/s00011-011-0348-z 21625968
67. Nitric oxide is an important mediator of renal tubular epithelial cell death in vitro and in murine experimental hydronephrosis. Kipari T, Cailhier JF, Ferenbach D, Watson S, Houlberg K, Walbaum D, Clay S, Savill J, Hughes J, Am J Pathol 2006 169 2 388 399 10.2353/ajpath.2006.050964 16877341 (Pubitemid 44156301)
68. Macrophages and kidney transplantation. Chadban SJ, Wu H, Hughes J, Semin Nephrol 2010 30 3 278 289 10.1016/j.semnephrol.2010.03.009 20620672
69. Microvascular destruction identifies murine allografts that cannot be rescued from airway fibrosis. Babu AN, Murakawa T, Thurman JM, Miller EJ, Henson PM, Zamora MR, Voelkel NF, Nicolls MR, J Clin Invest 2007 117 12 3774 3785 10.1172/JCI32311 18060031 (Pubitemid 350224088)
70. CD4+ T cells and complement independently mediate graft ischemia in the rejection of mouse orthotopic tracheal transplants. Khan MA, Jiang X, Dhillon G, Beilke J, Holers VM, Atkinson C, Tomlinson S, Nicolls MR, Circ Res 2011 109 11 1290 1301 10.1161/CIRCRESAHA.111.250167 21998328
71. Microvascular destruction in renal transplant rejection. Bishop GA, Waugh JA, Landers DV, Krensky AM, Hall BM, Transplantation 1989 48 3 408 414 10.1097/00007890-198909000-00011 2476878 (Pubitemid 19236503)
72. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA, Transplantation 1993 56 1 69 75 10.1097/00007890-199307000-00012 8333070 (Pubitemid 23220574)
73. Microvascular changes in small airways predispose to obliterative bronchiolitis after lung transplantation. Luckraz H, Goddard M, McNeil K, Atkinson C, Charman SC, Stewart S, Wallwork J, J Heart Lung Transplant Official Pub Int Soc Heart Transplant 2004 23 5 527 531 (Pubitemid 38595735)
74. Is obliterative bronchiolitis in lung transplantation associated with microvascular damage to small airways? Luckraz H, Goddard M, McNeil K, Atkinson C, Sharples LD, Wallwork J, Ann Thorac Surg 2006 82 4 1212 1218 10.1016/j.athoracsur.2006.03.070 16996910 (Pubitemid 44402309)
75. WNT7b mediates macrophage-induced programmed cell death in patterning of the vasculature. Lobov IB, Rao S, Carroll TJ, Vallance JE, Ito M, Ondr JK, Kurup S, Glass DA, Patel MS, Shu W, Morrisey EE, McMahon AP, Karsenty G, Lang RA, Nature 2005 437 7057 417 421 10.1038/nature03928 16163358 (Pubitemid 41613504)
76. Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Adair A, Mitchell DR, Kipari T, Qi F, Bellamy CO, Robertson F, Hughes J, Marson LP, Transplantation 2007 83 12 1542 1550 10.1097/01.tp.0000266689.93615.cd 17589335 (Pubitemid 46987904)
77. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension. Tian W, Jiang X, Tamosiuniene R, Sung YK, Qian J, Dhillon G, Gera L, Farkas L, Rabinovitch M, Zamanian RT, Inayathullah M, Fridlib M, Rajadas J, Peters-Golden M, Voelkel NF, Nicolls MR, Sci Transl Med 2013 5 200 200ra117 23986401
78. Macrophage regulation of tumor responses to anticancer therapies. De Palma M, Lewis CE, Cancer Cell 2013 23 3 277 286 10.1016/j.ccr.2013.02.013 23518347
79. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. Welford AF, Biziato D, Coffelt SB, Nucera S, Fisher M, Pucci F, Di Serio C, Naldini L, De Palma M, Tozer GM, Lewis CE, J Clin Invest 2011 121 5 1969 1973 10.1172/JCI44562 21490397
80. The interplay between macrophages and angiogenesis in development, tissue injury and regeneration. Nucera S, Biziato D, De Palma M, Int J Dev Biol 2011 55 4-5 495 503 21732273
81. TIE2-expressing monocytes/macrophages regulate revascularization of the ischemic limb. Patel AS, Smith A, Nucera S, Biziato D, Saha P, Attia RQ, Humphries J, Mattock K, Grover SP, Lyons OT, Guidotti LG, Siow R, Ivetic A, Egginton S, Waltham M, Naldini L, De Palma M, Modarai B, EMBO Mol Med 2013 5 6 858 869 10.1002/emmm.201302752 23653322
82. Harnessing the immune system for the treatment of breast cancer. Jiang X, J Zhejiang Univ Sci B 2014 15 1 1 15 24390741
83. Tie2-dependent VHL knockdown promotes airway microvascular regeneration and attenuates invasive growth of Aspergillus fumigatus. Jiang X, Hsu JL, Tian W, Yuan K, Olcholski M, de Jesus PV, Semenza GL, Nicolls MR, J Mol Med (Berl) 2013 91 9 1081 93 10.1007/s00109-013-1063-8 23797537
84. Vitamin D: modulator of the immune system. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C, Curr Opin Pharmacol 2010 10 4 482 496 10.1016/j.coph.2010.04.001 20427238
85. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Hume DA, MacDonald KP, Blood 2012 119 8 1810 1820 10.1182/blood-2011-09-379214 22186992
86. Shaping gene expression in activated and resting primary macrophages by IL-10. Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ, J Immunol 2002 169 5 2253 2263 12193690 (Pubitemid 34920965)
87. Corticosteroid receptors, macrophages and cardiovascular disease. Rickard AJ, Young MJ, J Mole Endocrinol 2009 42 6 449 459 10.1677/JME-08-0144
88. Regulation of immune responses by prostaglandin E2. Kalinski P, J Immunol 2012 188 1 21 28 10.4049/jimmunol.1101029 22187483
89. Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. Mellor AL, Baban B, Chandler PR, Manlapat A, Kahler DJ, Munn DH, J Immunol 2005 175 9 5601 5605 16237046 (Pubitemid 41508038)
90. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. Dillon S, Agrawal S, Banerjee K, Letterio J, Denning TL, Oswald-Richter K, Kasprowicz DJ, Kellar K, Pare J, van Dyke T, Ziegler S, Unutmaz D, Pulendran B, J Clin Invest 2006 116 4 916 928 10.1172/JCI27203 16543948
91. Human regulatory macrophages. Hutchinson JA, Riquelme P, Geissler EK, Fandrich F, Methods Mole Biol 2011 677 181 192
92. Cutting Edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. Hutchinson JA, Riquelme P, Sawitzki B, Tomiuk S, Miqueu P, Zuhayra M, Oberg HH, Pascher A, Lutzen U, Janssen U, Broichhausen C, Renders L, Thaiss F, Scheuermann E, Henze E, Volk HD, Chatenoud L, Lechler RI, Wood KJ, Kabelitz D, Schlitt HJ, Geissler EK, Fändrich F, J Immunol 2011 187 5 2072 2078 10.4049/jimmunol.1100762 21804023
93. IFN-gamma-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Riquelme P, Tomiuk S, Kammler A, Fandrich F, Schlitt HJ, Geissler EK, Hutchinson JA, Mole Therapy J Am Soc Gene Therapy 2013 21 2 409 422 10.1038/mt.2012.168
94. Learning from rejection: What transplantation teaches us about (other) vascular pathologies. Mitchell RN, J Autoimmun 2013 45 80 89 23830871
95. The pathogenesis of coronary arteriosclerosis ("chronic rejection") in transplanted hearts. Libby P, Tanaka H, Clin Transplant 1994 8 3 Pt 2 313 318 7520306 (Pubitemid 24163497)
96. Upregulation of cytokines associated with macrophage activation in the Lewis-to-F344 rat transplantation model of chronic cardiac rejection. Russell ME, Wallace AF, Hancock WW, Sayegh MH, Adams DH, Sibinga NE, Wyner LR, Karnovsky MJ, Transplantation 1995 59 4 572 578 10.1097/00007890-199559040-00023 7533347
97. Cardiac allograft vasculopathy - the cellular attack. Hutchinson IV, Z Kardiol 2000 89 Suppl 9 /16 X/20
98. Chronic rejection. Libby P, Pober JS, Immunity 2001 14 4 387 397 10.1016/S1074-7613(01)00119-4 11336684 (Pubitemid 32441591)
99. Intimal fibrosis in human cardiac allograft vasculopathy. Huibers M, De Jonge N, Van Kuik J, Koning ES, Van Wichen D, Dullens H, Schipper M, De Weger R, Transplant Immunol 2011 25 2-3 124 132
100. Macrophage depletion suppresses cardiac allograft vasculopathy in mice. Kitchens WH, Chase CM, Uehara S, Cornell LD, Colvin RB, Russell PS, Madsen JC, Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg 2007 7 12 2675 2682 10.1111/j.1600-6143.2007.01997.x (Pubitemid 350045773)
101. Prevention of functional, structural, and molecular changes of chronic rejection of rat renal allografts by a specific macrophage inhibitor. Azuma H, Nadeau KC, Ishibashi M, Tilney NL, Transplantation 1995 60 12 1577 1582 10.1097/00007890-199560120-00034 8545893 (Pubitemid 26012696)
102. Very late heart transplant rejection is associated with microvascular injury, complement deposition and progression to cardiac allograft vasculopathy. Loupy A, Cazes A, Guillemain R, Amrein C, Hedjoudje A, Tible M, Pezzella V, Fabiani JN, Suberbielle C, Nochy D, Hill GS, Empana JP, Jouven X, Bruneval P, Duong Van Huyen JP, Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg 2011 11 7 1478 1487 10.1111/j.1600-6143.2011.03563.x
103. An artificial nanoemulsion carrying paclitaxel decreases the transplant heart vascular disease: a study in a rabbit graft model. Lourenco-Filho DD, Maranhao RC, Mendez-Contreras CA, Tavares ER, Freitas FR, Stolf NA, J Thorac Cardiovasc Surg 2011 141 6 1522 1528 10.1016/j.jtcvs.2010.08.032 21458008
104. Spironolactone ameliorates transplant vasculopathy in renal chronic transplant dysfunction in rats. Waanders F, Rienstra H, Boer MW, Zandvoort A, Rozing J, Navis G, van Goor H, Hillebrands JL, Am J Physiol Renal Physiol 2009 296 5 1072 1079 10.1152/ajprenal.90643.2008 19244402
105. Tumor necrosis factor receptor -1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Suzuki J, Cole SE, Batirel S, Kosuge H, Shimizu K, Isobe M, Libby P, Mitchell RN, Am J Transplant Official J Am Soc Transplant Am Soc Transplant Surg 2003 3 8 968 976 10.1034/j.1600-6143. 2003.00164.x (Pubitemid 36917542)
106. Interferon-gamma deficiency prevents coronary arteriosclerosis but not myocardial rejection in transplanted mouse hearts. Nagano H, Mitchell RN, Taylor MK, Hasegawa S, Tilney NL, Libby P, J Clin Invest 1997 100 3 550 557 10.1172/JCI119564 9239401 (Pubitemid 27340501)
107. Interferon-gamma axis in graft arteriosclerosis. Tellides G, Pober JS, Circ Res 2007 100 5 622 632 10.1161/01.RES.0000258861.72279.29 17363708 (Pubitemid 46594876)
108. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U, J Exp Med 2002 195 2 245 257 10.1084/jem.20011022 11805151 (Pubitemid 34461268)
109. Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis. Hillebrands JL, Klatter FA, van den Hurk BM, Popa ER, Nieuwenhuis P, Rozing J, J Clin Invest 2001 107 11 1411 1422 10.1172/JCI10233 11390423 (Pubitemid 32522035)
110. Smooth muscle cells, but not myocytes, of host origin in transplanted human hearts. Glaser R, Lu MM, Narula N, Epstein JA, Circulation 2002 106 1 17 19 10.1161/01.CIR.0000021923.58307.8F 12093763 (Pubitemid 34747435)
111. CXCR3 expression in human central nervous system diseases. Goldberg SH, van der Meer P, Hesselgesser J, Jaffer S, Kolson DL, Albright AV, Gonzalez-Scarano F, Lavi E, Neuropathol App Neurobiol 2001 27 2 127 138 10.1046/j.1365-2990.2001.00312.x (Pubitemid 32591969)
112. Stromal cell-derived factor-1 and CXCR4 interaction is critical for development of transplant arteriosclerosis. Sakihama H, Masunaga T, Yamashita K, Hashimoto T, Inobe M, Todo S, Uede T, Circulation 2004 110 18 2924 2930 10.1161/01.CIR.0000146890.93172.6C 15505104 (Pubitemid 39473619)
113. Differential influence of chemokine receptors CCR2 and CXCR3 in development of atherosclerosis in vivo. Veillard NR, Steffens S, Pelli G, Lu B, Kwak BR, Gerard C, Charo IF, Mach F, Circulation 2005 112 6 870 878 10.1161/CIRCULATIONAHA.104.520718 16061736 (Pubitemid 41170074)
114. CCL11 (Eotaxin) induces CCR3-dependent smooth muscle cell migration. Kodali RB, Kim WJ, Galaria II, Miller C, Schecter AD, Lira SA, Taubman MB, Arterioscler Thromb Vasc Biol 2004 24 7 1211 1216 10.1161/01.ATV.0000131654. 90788.f5 15130922 (Pubitemid 38880010)
115. Vascular remodeling in transplant vasculopathy. Mitchell RN, Libby P, Circ Res 2007 100 7 967 978 10.1161/01.RES.0000261982.76892.09 17431198 (Pubitemid 46598921)
116. CCR1 antagonists: what have we learned from clinical trials. Gladue RP, Brown MF, Zwillich SH, Curr Top Med Chem 2010 10 13 1268 1277 10.2174/156802610791561237 20536425
117. Dual targeting of CCR2 and CCR5: therapeutic potential for immunologic and cardiovascular diseases. Zhao Q, J Leukoc Biol 2010 88 1 41 55 10.1189/jlb.1009671 20360402
118. A common rejection module (CRM) for acute rejection across multiple organs identifies novel therapeutics for organ transplantation. Khatri P, Roedder S, Kimura N, De Vusser K, Morgan AA, Gong Y, Fischbein MP, Robbins RC, Naesens M, Butte AJ, Sarwal MM, J Exp Med 2013 210 11 2205 2221 10.1084/jem.20122709 24127489
119. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. Turnquist HR, Raimondi G, Zahorchak AF, Fischer RT, Wang Z, Thomson AW, J Immunol 2007 178 11 7018 7031 17513751 (Pubitemid 46847428)
120. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Ehrchen J, Steinmuller L, Barczyk K, Tenbrock K, Nacken W, Eisenacher M, Nordhues U, Sorg C, Sunderkotter C, Roth J, Blood 2007 109 3 1265 1274 17018861 (Pubitemid 46220679)